Literature DB >> 26861885

Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis.

Susan E Yount1, Jennifer L Beaumont2, Shih-Yin Chen3, Karen Kaiser2, Katy Wortman2, David L Van Brunt3, Jeffrey Swigris4, David Cella2.   

Abstract

PURPOSE: Idiopathic pulmonary fibrosis (IPF) produces symptoms and activity limitations that impair health-related quality of life (HRQOL). The Patient-Reported Outcomes Measurement Information System(®) (PROMIS(®)) includes measures of self-reported health and HRQOL for a range of conditions. This study evaluated the HRQOL of individuals with IPF using PROMIS measures and examined associations between HRQOL and key symptoms or supplemental oxygen need.
METHODS: Individuals who reported being told by a doctor that they have IPF completed an online battery of measures at baseline and 7-10 days later (for test-retest reliability). Measures included a brief survey of demographic and health-related questions, the PROMIS-29 profile, the Modified Medical Research Council Dyspnea Scale (MMRC), PROMIS dyspnea severity short form, A Tool to Assess Quality of life in IPF (ATAQ-IPF) and one cough item from the Functional Assessment of Chronic Illness Therapy (FACIT).
RESULTS: 220 individuals were included in the final sample. Except for sleep disturbance, all PROMIS domain scores significantly (p < .01) differed by MMRC level. Supplemental oxygen users were more impaired than non-users in fatigue, physical function, and social role participation (p < 0.01). The test-retest reliability was acceptable to excellent (>0.7) for all scales, but was lower for sleep disturbance (0.64).
CONCLUSIONS: People with IPF report substantial deficits in HRQOL across a range of PROMIS domains, and deficits vary by dyspnea and cough severity. These deficits warrant monitoring in clinical practice and consideration when investigating new therapies. Further research is required to further evaluate the psychometric performance of the PROMIS-29 in IPF.

Entities:  

Keywords:  Health-related quality of life; Idiopathic pulmonary fibrosis; PROMIS

Mesh:

Year:  2016        PMID: 26861885     DOI: 10.1007/s00408-016-9850-y

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  23 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  The MRC breathlessness scale.

Authors:  Chris Stenton
Journal:  Occup Med (Lond)       Date:  2008-05       Impact factor: 1.611

Review 3.  Idiopathic pulmonary fibrosis: diagnosis and epidemiology.

Authors:  Amy L Olson; Jeffrey J Swigris
Journal:  Clin Chest Med       Date:  2012-03       Impact factor: 2.878

4.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

5.  Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel.

Authors:  Honghu Liu; David Cella; Richard Gershon; Jie Shen; Leo S Morales; William Riley; Ron D Hays
Journal:  J Clin Epidemiol       Date:  2010-08-05       Impact factor: 6.437

6.  Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form.

Authors:  Monique Hinchcliff; Jennifer L Beaumont; Krishna Thavarajah; John Varga; Anh Chung; Sofia Podlusky; Mary Carns; Rowland W Chang; David Cella
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

7.  Brief, valid measures of dyspnea and related functional limitations in chronic obstructive pulmonary disease (COPD).

Authors:  Susan E Yount; Seung W Choi; David Victorson; Bernice Ruo; David Cella; Susan Anton; Alan Hamilton
Journal:  Value Health       Date:  2011 Mar-Apr       Impact factor: 5.725

8.  Clinical validity of PROMIS Depression, Anxiety, and Anger across diverse clinical samples.

Authors:  Benjamin D Schalet; Paul A Pilkonis; Lan Yu; Nathan Dodds; Kelly L Johnston; Susan Yount; William Riley; David Cella
Journal:  J Clin Epidemiol       Date:  2016-02-27       Impact factor: 6.437

9.  Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.

Authors:  Ganesh Raghu; Shih-Yin Chen; Wei-Shi Yeh; Brad Maroni; Qian Li; Yuan-Chi Lee; Harold R Collard
Journal:  Lancet Respir Med       Date:  2014-05-27       Impact factor: 30.700

10.  Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form.

Authors:  Fang-Ju Lin; A Simon Pickard; Jerry A Krishnan; Min J Joo; David H Au; Shannon S Carson; Suzanne Gillespie; Ashley G Henderson; Peter K Lindenauer; Mary Ann McBurnie; Richard A Mularski; Edward T Naureckas; William M Vollmer; Todd A Lee
Journal:  BMC Med Res Methodol       Date:  2014-06-16       Impact factor: 4.615

View more
  32 in total

1.  Measurement invariance and general population reference values of the PROMIS Profile 29 in the UK, France, and Germany.

Authors:  Felix Fischer; Chris Gibbons; Joël Coste; Jose M Valderas; Matthias Rose; Alain Leplège
Journal:  Qual Life Res       Date:  2018-01-19       Impact factor: 4.147

Review 2.  Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

Authors:  Mirjam J G van Manen; J J Miranda Geelhoed; Nelleke C Tak; Marlies S Wijsenbeek
Journal:  Ther Adv Respir Dis       Date:  2017-01-01       Impact factor: 4.031

3.  Use of PROMIS-29® in US Veterans: Diagnostic Concordance and Domain Comparisons with the General Population.

Authors:  Sherri L LaVela; Bella Etingen; Scott Miskevics; David Cella
Journal:  J Gen Intern Med       Date:  2019-05-29       Impact factor: 5.128

4.  Effectiveness and Safety of Chinese Medicine for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.

Authors:  Qi Wu; Yao Zhou; Fan-Chao Feng; Xian-Mei Zhou
Journal:  Chin J Integr Med       Date:  2018-01-15       Impact factor: 1.978

5.  Lived experiences of the disease journey among patients with idiopathic pulmonary fibrosis.

Authors:  Yang Lyu; Yanrui Jia; Fengli Gao; Ya-Ling Huang; Frances Lin
Journal:  Int J Nurs Sci       Date:  2021-03-04

6.  Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid.

Authors:  Jonathan Savitz; Bart N Ford; Hung-Wen Yeh; Elisabeth Akeman; Kelly Cosgrove; Ashley N Clausen; Christopher Martell; Namik Kirlic; Jessica Santiago; T Kent Teague; Michael R Irwin; Martin P Paulus; Robin L Aupperle
Journal:  Psychol Med       Date:  2020-11-25       Impact factor: 10.592

Review 7.  Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis.

Authors:  Catharina C Moor; Peter Heukels; Mirjam Kool; Marlies S Wijsenbeek
Journal:  Front Med (Lausanne)       Date:  2017-12-20

8.  mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis.

Authors:  Kaisa Rajala; Juho T Lehto; Eva Sutinen; Hannu Kautiainen; Marjukka Myllärniemi; Tiina Saarto
Journal:  ERJ Open Res       Date:  2017-12-14

9.  Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.

Authors:  Michael Kreuter; Jeff Swigris; David Pittrow; Silke Geier; Jens Klotsche; Antje Prasse; Hubert Wirtz; Dirk Koschel; Stefan Andreas; Martin Claussen; Christian Grohé; Henrike Wilkens; Lars Hagmeyer; Dirk Skowasch; Joachim F Meyer; Joachim Kirschner; Sven Gläser; Felix J F Herth; Tobias Welte; Claus Neurohr; Martin Schwaiblmair; Matthias Held; Thomas Bahmer; Marion Frankenberger; Jürgen Behr
Journal:  Respir Res       Date:  2017-07-14

10.  Health-related quality of life among adults with diverse rare disorders.

Authors:  Kathleen R Bogart; Veronica L Irvin
Journal:  Orphanet J Rare Dis       Date:  2017-12-07       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.